Advancing Dermal Interstitial Fluid as a Viable Matrix for Accessible Diagnostics
Abstract
Dermal interstitial fluid (ISF) remains an untapped resource for diagnostic testing despite containing many of the same biomarkers found in blood with simpler processing requirements. Although ISF's potential is clear, its use in diagnostics has been largely limited to continuous glucose monitoring due to historically difficult extraction processes. This presentation covers DermiSense's approach to establishing ISF as a mainstream diagnostic matrix through a minimally invasive microsampling patch platform. The technology's potential is demonstrated through cortisol measurement using both standard ELISA methods and integrated biosensors, highlighting the platform's flexibility. Progress in technical validation and strategic commercialization planning represents the first steps toward creating a foundation for ISF to become another gold standard matrix for biomarker analysis — if the "valley of death" between innovation and market adoption can be successfully navigated.
Biography
John Strang brings a unique blend of leadership from fields in virtual healthcare and quality management in manufacturing. His experience includes spearheading the development of a web-based application designed for the stringent demands of quality control in medical device and aerospace manufacturing, and a strategic role in driving revenue growth within the virtual healthcare industry at Vida Health. John has proven his ability to lead teams towards innovation and market success. His diverse background, which spans from tech startups to major league sports, emphasizes his adaptable and forward-thinking approach to leadership. John's operational expertise and product management skills have consistently resulted in enhanced cross-departmental collaboration, productivity, and successful product launches.